Prasugrel Contraindication and P2Y12 Inhibitor Selection in Acute Coronary Syndrome Patients Managed Without PCI
1. Prasugrel is Not Indicated When PCI Is Not Planned
- Prasugrel is absolutely contraindicated in acute coronary syndrome (ACS) patients who will not undergo percutaneous coronary intervention (PCI) [1][2]3.
2. Evidence Underpinning the Contraindication
- In the pivotal TRITON‑TIMI 38 trial, prasugrel was administered only after coronary angiography confirmed that PCI would be performed; patients managed medically were excluded 1.
- The TRILOGY‑ACS trial, which compared prasugrel with clopidogrel in non‑ST‑elevation ACS patients managed with an ischemia‑guided (non‑invasive) strategy, showed no clinical benefit of prasugrel and similar bleeding rates 1.
3. Preferred P2Y12 Inhibitor for Non‑PCI ACS
- Ticagrelor (180 mg loading dose, then 90 mg twice daily) is the first‑line P2Y12 inhibitor for ACS patients who will not undergo PCI 3.
- Ticagrelor reduces major adverse cardiovascular events (MACE) and mortality in both invasively and medically managed ACS patients [1][2]3.
- The PLATO trial demonstrated ticagrelor’s superiority over clopidogrel in the 28 % of ACS patients who did not receive revascularisation, with consistent reductions in cardiovascular death, myocardial infarction, and stroke [1][3].
4. Alternative When Ticagrelor Is Not Feasible
- Clopidogrel (600 mg loading dose, then 75 mg daily) is an acceptable alternative when ticagrelor is unavailable, not tolerated, or contraindicated 3.
5. Algorithm for P2Y12 Inhibitor Selection According to Revascularisation Strategy
| Revascularisation Strategy | Recommended P2Y12 Inhibitor(s) | Contraindicated |
|---|---|---|
| PCI planned or performed | Ticagrelor or Prasugrel (after coronary anatomy is known) | – |
| Coronary artery bypass grafting (CABG) planned | Ticagrelor or Clopidogrel | Prasugrel |
| Medical management only (no revascularisation) | Ticagrelor or Clopidogrel | Prasugrel |
Sources: [2][3]1
6. Special Populations and Absolute Contraindications
- Prior stroke or transient ischaemic attack: Prasugrel must never be used (Class III Harm); ticagrelor is preferred [1][3].
- Active bleeding or intracranial haemorrhage: Both ticagrelor and prasugrel are contraindicated; clopidogrel may be used if dual antiplatelet therapy (DAPT) remains indicated 2.
- High bleeding risk or requirement for oral anticoagulation: Clopidogrel is preferred over ticagrelor or prasugrel 3.
7. Duration of Dual Antiplatelet Therapy
- All ACS patients should receive 12 months of DAPT (aspirin 75–100 mg daily plus a P2Y12 inhibitor) irrespective of whether they undergo PCI, CABG, or medical management 3.
8. Adjunctive Gastro‑Protection
- A proton‑pump inhibitor should be prescribed to every patient on DAPT to lower the risk of gastrointestinal bleeding (Class I recommendation) 3.